A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.
The board is fielding shareholder demands for a clear plan to boost the bank’s stock price – and a strategy to compete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback